TY - JOUR
T1 - Clinically relevant microRNAs in ovarian cancer
AU - Zhang, Shu
AU - Lu, Zhen
AU - Unruh, Anna K.
AU - Ivan, Cristina
AU - Baggerly, Keith A.
AU - Calin, George A.
AU - Li, Zongfang
AU - Bast, Robert
AU - Le, Xiao Feng
N1 - Publisher Copyright:
©2014 AACR.
PY - 2015/3/1
Y1 - 2015/3/1
N2 - microRNAs (miRNAs/miRs) belong to a class of small noncoding RNAs that can negatively regulate messenger RNA (mRNA) expression of target genes. miRNAs are involved inmultiple aspects of ovarian cancer cell dysfunction and the phenotype of ovarian cancer cells can be modified by targeting miRNA expression. miRNA profiling has detected a number of candidate miRNAs with the potential to regulatemanyimportant biologic functions in ovarian cancer, but their role still needs to be clarified, given the remarkable heterogeneity among ovarian cancers and the contextdependent role of miRNAs. This review summarizes the data collected fromTheCancer Genome Atlas (TCGA) and several other genome-wide projects to identify dysregulated miRNAs in ovarian cancers. Copy number variations (CNVs), epigenetic alterations, and oncogenic mutations are also discussed that affect miRNA levels in ovarian disease. Emphasis is given to the role of particular miRNAs in altering expression of genes in human ovarian cancers with the potential to provide diagnostic, prognostic, and therapeutic targets. Particular attention has been given to TP53, BRCA1/ 2, CA125 (MUC16), HE4 (WFDC2), and imprinted genes such as ARHI (DIRAS3). A better understanding of the abnormalities in miRNA expression and downstream transcriptional and biologic consequences will provide leads for more effective biomarkers and translational approaches in the management of ovarian.
AB - microRNAs (miRNAs/miRs) belong to a class of small noncoding RNAs that can negatively regulate messenger RNA (mRNA) expression of target genes. miRNAs are involved inmultiple aspects of ovarian cancer cell dysfunction and the phenotype of ovarian cancer cells can be modified by targeting miRNA expression. miRNA profiling has detected a number of candidate miRNAs with the potential to regulatemanyimportant biologic functions in ovarian cancer, but their role still needs to be clarified, given the remarkable heterogeneity among ovarian cancers and the contextdependent role of miRNAs. This review summarizes the data collected fromTheCancer Genome Atlas (TCGA) and several other genome-wide projects to identify dysregulated miRNAs in ovarian cancers. Copy number variations (CNVs), epigenetic alterations, and oncogenic mutations are also discussed that affect miRNA levels in ovarian disease. Emphasis is given to the role of particular miRNAs in altering expression of genes in human ovarian cancers with the potential to provide diagnostic, prognostic, and therapeutic targets. Particular attention has been given to TP53, BRCA1/ 2, CA125 (MUC16), HE4 (WFDC2), and imprinted genes such as ARHI (DIRAS3). A better understanding of the abnormalities in miRNA expression and downstream transcriptional and biologic consequences will provide leads for more effective biomarkers and translational approaches in the management of ovarian.
UR - http://www.scopus.com/inward/record.url?scp=84928032478&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84928032478&partnerID=8YFLogxK
U2 - 10.1158/1541-7786.MCR-14-0424
DO - 10.1158/1541-7786.MCR-14-0424
M3 - Review article
C2 - 25304686
AN - SCOPUS:84928032478
SN - 1541-7786
VL - 13
SP - 393
EP - 401
JO - Molecular Cancer Research
JF - Molecular Cancer Research
IS - 3
ER -